Novartis Delves Further into AAV Gene Therapies with US$1.65 B Voyager Deal
By Lucy Haggerty
Pharma Deals Review: Vol 2022 Issue 3 (Table of Contents)
Published: 16 Mar-2022
DOI: 10.3833/pdr.v2022.i3.2678 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
Voyager Therapeutics has entered into an option agreement with Novartis to license next-generation adeno-associated virus capsids for gene therapies targeting undisclosed neurological diseases...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS